[New combination chemotherapy of adult acute nonlymphocytic leukemia]. 1985

S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009353 Zinostatin An enediyne that alkylates DNA and RNA like MITOMYCIN does, so it is cytotoxic. Neocarzinostatin
D011239 Prednisolone A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. Di-Adreson-F,Predate,Predonine,Di Adreson F,DiAdresonF
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D005260 Female Females

Related Publications

S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
August 1988, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
August 1990, Gan to kagaku ryoho. Cancer & chemotherapy,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
November 1993, Chinese medical journal,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
May 1984, The Medical clinics of North America,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
November 1984, Blood,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
April 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
September 1984, Mayo Clinic proceedings,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
November 1977, Cancer treatment reports,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
February 1976, Clinical pharmacology and therapeutics,
S Nakamura, and T Yoshida, and S Ohtake, and K Itoh, and K Kobayashi, and J Nakanishi, and T Matsuda, and H Natori, and K Egami, and K Tanaka
July 1973, Cancer,
Copied contents to your clipboard!